John P. Hamill
2018 - Cellectar Biosciences
In 2018, John P. Hamill earned a total compensation of $11.7K as Former Interim Chief Financial Officer at Cellectar Biosciences, a 93% decrease compared to previous year.
Compensation breakdown
| Other | $11,742 |
|---|---|
| Total | $11,742 |
Hamill received $11.7K in other compensation, accounting for 100% of the total pay in 2018.
Rankings
In 2018, John P. Hamill's compensation ranked 14,212th out of 14,244 executives tracked by ExecPay.
| Classification | Ranking | Percentile |
|---|---|---|
All | 14,212 out of 14,244 | 0th |
Division Manufacturing | 5,758 out of 5,765 | 0th |
Major group Chemicals And Allied Products | 2,126 out of 2,128 | 0th |
Industry group Drugs | 1,815 out of 1,817 | 0th |
Industry Pharmaceutical Preparations | 1,390 out of 1,391 | 0th |
Source: SEC filing on April 29, 2019.
Hamill's colleagues
We found four more compensation records of executives who worked with John P. Hamill at Cellectar Biosciences in 2018.
News
Aprea Therapeutics CFO John Hamill's 2023 pay jumps 62% to $908K
April 25, 2024
Discovery Laboratories CEO Craig Fraser's 2022 pay falls 50% to $941K
June 29, 2023
Discovery Laboratories CEO Craig Fraser's 2021 pay jumps 144% to $1.9M
May 11, 2022
Discovery Laboratories COO Eric Curtis receives $1.8M in 2020
April 30, 2021
Cellectar Biosciences CEO James Caruso's 2018 pay falls 23% to $770K
April 29, 2019